AER-001 (Aerium Therapeutics)

N/A

Report date: 2024/12/20 17:16:48

Base Information

Drug NameAER-001 (Aerium Therapeutics)
Drug Alias NameAER-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVirus internalization inhibitorsCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCentre Hospitalier Universitaire VaudoisSwiss Federal Institute Of Technology
China Registration ClassN/A

Develop Information

Active CompaniesAerium Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A